enVVeno Medical (NASDAQ:NVNO) Issues Quarterly Earnings Results

enVVeno Medical (NASDAQ:NVNO) issued its quarterly earnings data on Thursday. The company reported ($6.29) EPS for the quarter, missing the consensus estimate of ($3.27) by ($3.02), FiscalAI reports.

enVVeno Medical Price Performance

NVNO stock traded down $0.29 during midday trading on Friday, hitting $6.73. The stock had a trading volume of 19,184 shares, compared to its average volume of 39,484. The firm has a market cap of $4.64 million, a price-to-earnings ratio of -0.35 and a beta of 1.29. The business has a 50-day moving average of $8.96 and a two-hundred day moving average of $10.32. enVVeno Medical has a 52-week low of $6.52 and a 52-week high of $25.90.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of enVVeno Medical in a research report on Friday, September 25th. Zacks Research raised shares of enVVeno Medical to a “hold” rating in a research note on Tuesday, July 7th. Wall Street Zen upgraded shares of enVVeno Medical to a “hold” rating in a report on Saturday, October 24th. Finally, LADENBURG THALM/SH SH upgraded shares of enVVeno Medical from a “hold” rating to a “strong-buy” rating in a report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold”.

enVVeno Medical Company Profile

enVVeno Medical Corporation (NASDAQ:NVNO) is a late-stage medical device company focused on developing bioprosthetic, or tissue-based, treatments for venous disease. Its primary focus is chronic venous insufficiency, a condition in which damaged or absent valves allow blood to flow backward in the veins and can cause swelling, pain, skin changes and ulcers.

The company’s lead product is the VenoValve, a surgically implanted bioprosthetic valve designed to restore one-way blood flow in the deep veins of the leg.